Abliva AB Interim Report January – September 2021
Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Press releases
Abliva AB Interim Report January – June 2021
Second quarter summary
Abliva AB Interim Report January – March 2021
First quarter summary
Abliva AB Year-End Report January – December 2020
2020 summary
Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Interim Report January-March 2020
Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for […]
NeuroVive Pharmaceutical AB Year End Report January – December 2019
Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...
NeuroVive Pharmaceutical AB Interim Report January – September 2019
Continued progress in KL1333.
NeuroVive Pharmaceutical AB Interim Report January – June 2019
Focus on genetic mitochondrial diseases
NeuroVive Pharmaceutical AB Interim Report January – March 2019
First subjects enrolled in the KL1333 study
NeuroVive Pharmaceutical AB Year End Report January – December 2018
Positioned for clinical progress